272 related articles for article (PubMed ID: 21741344)
1. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
4. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
Unal S; Hazirolan T; Eldem G; Gumruk F
Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
[TBL] [Abstract][Full Text] [Related]
5. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
Chen AC; Peng CT; Wu SF; Wu KH; Chiang IP; Tsai CH
Hemoglobin; 2006; 30(2):209-14. PubMed ID: 16798645
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
8. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
[TBL] [Abstract][Full Text] [Related]
9. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases.
Prati D; Maggioni M; Milani S; Cerino M; Cianciulli P; Coggi G; Forni GL; Magnano C; Meo A; Gramignoli R; Rebulla P; Fiorelli G; Cappellini MD;
Haematologica; 2004 Oct; 89(10):1179-86. PubMed ID: 15477201
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report.
Panigrahi I; Vaidya PC; Bansal D; Marwaha RK
J Pediatr Hematol Oncol; 2012 Jan; 34(1):51-3. PubMed ID: 22215098
[TBL] [Abstract][Full Text] [Related]
11. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
[TBL] [Abstract][Full Text] [Related]
12. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
Voskaridou E; Plata E; Douskou M; Sioni A; Mpoutou E; Christoulas D; Dimopoulou M; Terpos E
Ann Hematol; 2011 Jan; 90(1):11-5. PubMed ID: 20661572
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
Pathare A; Taher A; Daar S
Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501
[TBL] [Abstract][Full Text] [Related]
17. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
Cassinerio E; Roghi A; Orofino N; Pedrotti P; Zanaboni L; Poggiali E; Giuditta M; Consonni D; Cappellini MD
Ann Hematol; 2015 Jun; 94(6):939-45. PubMed ID: 25563596
[TBL] [Abstract][Full Text] [Related]
18. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.
Voskaridou E; Plata E; Douskou M; Papadakis M; Delaki EE; Christoulas D; Terpos E
Br J Haematol; 2010 Jan; 148(2):332-4. PubMed ID: 19863539
[No Abstract] [Full Text] [Related]
19. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
[TBL] [Abstract][Full Text] [Related]
20. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
Haematologica; 2011 Jan; 96(1):48-54. PubMed ID: 21071497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]